搜索
Traws Pharma Inc
TRAW添加自选
1.700USD
+0.070+4.29%
交易中 （美东）报价延迟15分钟
15.42M总市值
2.04市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.29%
5天
0.00%
1月
+6.92%
6月
-21.66%
今年开始到现在
+50.44%
1年
+37.10%
TradingKey Traws Pharma Inc股票评分
单位: USD 更新时间: 2026-05-14操作建议
Traws Pharma Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名97/382位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价5.50。中期看，股价处于下降通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Traws Pharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Traws Pharma Inc亮点
亮点风险
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
业绩高增长
公司营业收入稳步增长，连续3年增长1134.51%
业绩增长期
公司处于发展阶段，最新年度总收入2.79M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值1.95，处于3年历史高位
机构加仓
最新机构持股3.52M股，环比增加23.92%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率5.74
分析师目标
根据
2
位分析师
强力买入
评级
5.500
目标均价
+219.77%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Traws Pharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Traws Pharma Inc简介
Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
公司代码TRAW
公司Traws Pharma Inc
CEODukes (Iain D)
网址https://www.trawspharma.com/
相关品种
